Advertisement
BIO vs DHR
Which Stock Would AI Choose? Bio-Rad Laboratories (BIO) vs. Danaher (DHR) Stock Comparison
Key Takeaways
- BIO has delivered stronger recent momentum, with shares rising over 40% in the past six months and trading near 52-week highs around $396.
- DHR maintains a larger scale with diversified exposure across biotechnology, life sciences, and diagnostics, supported by consistent free cash flow generation.
- BIO reported Q2 2026 revenue of $651 million with standout growth in digital PCR instruments exceeding 20%, though overall revenue guidance reflects modest pressure.
- DHR achieved 3% core sales growth in Q2 2026, raised full-year EPS guidance, and completed the Masimo acquisition while announcing a new CEO.
- Both companies operate in the life sciences tools and diagnostics space, facing uneven academic and government demand alongside opportunities in high-growth molecular testing platforms.
- BIO trades at a premium valuation relative to earnings, while DHR offers greater stability and recurring revenue from consumables and services.
Introduction
Bio-Rad Laboratories (BIO) and Danaher Corporation (DHR) represent two established players in the life sciences and diagnostics sector. This comparison examines their business models, recent performance trends, and market positioning to assist investors and traders evaluating relative opportunities within healthcare instrumentation and consumables. The analysis draws on verifiable developments from recent weeks, including earnings reports, corporate actions, and sector dynamics, providing context for those seeking to understand performance contrasts in the current environment.
BIO Overview and Recent Performance
Bio-Rad Laboratories develops and manufactures products for life science research and clinical diagnostics markets, with notable positions in quality controls, antigens, and digital polymerase chain reaction (dPCR) platforms. In recent market activity, shares have shown resilience, climbing more than 40% over six months and approaching the 52-week high near $396 amid strength in digital PCR instrument revenue, which rose over 20% in Q2 2026. The company reported Q2 revenue of $651 million, essentially flat on a reported basis, with diagnostics returning to growth while life sciences faced funding constraints and softness in China. Management outlined restructuring initiatives targeting $30 million to $35 million in annualized savings and provided 2026 revenue guidance reflecting a possible modest decline to slight growth on a currency-neutral basis. Conference participation in September has kept focus on margin improvement efforts.
DHR Overview and Recent Performance
Danaher Corporation operates a diversified portfolio spanning biotechnology, life sciences, and diagnostics, emphasizing recurring revenue from consumables and services through its Danaher Business System. Recent performance reflects steady execution, with Q2 2026 revenue reaching $6.27 billion and 3% core sales growth, accelerating in non-respiratory segments. The company raised full-year EPS guidance following the early close of the approximately $9.8 billion Masimo acquisition and the appointment of a new president and chief executive officer in August. Shares have traded in a range around $212 amid broader sector dynamics, supported by consistent free cash flow and a quarterly dividend of $0.40 per share announced in September. Management has noted modest academic demand recovery alongside some bioprocessing shipment timing factors.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating the strongest alignment with prevailing market conditions earn placement in this focused section. Available bots encompass a wide array of trading styles, strategies, timeframes, performance metrics, and ticker sets, with many showing win rates and returns that vary based on backtested and live results. This resource allows traders to explore data-driven approaches suited to individual preferences. Review the Trending AI Robots page for detailed statistics and bot profiles.
Head-to-Head Comparison
Bio-Rad Laboratories focuses on specialized life science and diagnostics tools with exposure to molecular testing growth areas, while Danaher offers broader scale and recurring revenue streams across multiple end markets. Recent momentum favors BIO through share price appreciation tied to digital PCR wins, whereas DHR demonstrates greater stability via acquisitions, cost discipline, and cash generation. Risk factors for BIO include sensitivity to research funding cycles and higher valuation multiples, while DHR contends with integration execution and periodic demand variability in bioprocessing. Sector exposure overlaps in diagnostics and life sciences, yet DHR benefits from wider diversification. Market sentiment reflects cautious optimism for both amid uneven academic spending, with BIO showing sharper near-term price response to operational highlights.
Tickeron AI Verdict
Based on observable factors such as trend consistency in digital PCR momentum, relative share price stability near highs, and positioning within growth niches, Tickeron’s AI models currently assign a modestly higher probabilistic preference to BIO over DHR for short-term trend alignment. This assessment incorporates recent performance data and sector catalysts without implying certainty or future outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and DHR is a Buy.
BIO | DHR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 88 Overvalued | 8 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 87 | 77 | |
PRICE GROWTH RATING 1..100 | 39 | 53 | |
P/E GROWTH RATING 1..100 | 9 | 42 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for BIO (88). This means that DHR’s stock grew significantly faster than BIO’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BIO (100). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as BIO (87). This means that DHR’s stock grew similarly to BIO’s over the last 12 months.
BIO's Price Growth Rating (39) in the Medical Specialties industry is in the same range as DHR (53). This means that BIO’s stock grew similarly to DHR’s over the last 12 months.
BIO's P/E Growth Rating (9) in the Medical Specialties industry is somewhat better than the same rating for DHR (42). This means that BIO’s stock grew somewhat faster than DHR’s over the last 12 months.
| BIO | DHR | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 75% | 2 days ago 67% |
| Stochastic ODDS (%) | 2 days ago 77% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 55% |
| MACD ODDS (%) | 2 days ago 70% | 2 days ago 60% |
| TrendWeek ODDS (%) | 2 days ago 66% | 2 days ago 63% |
| TrendMonth ODDS (%) | 2 days ago 73% | 2 days ago 65% |
| Advances ODDS (%) | 11 days ago 66% | 5 days ago 54% |
| Declines ODDS (%) | 2 days ago 67% | 2 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 82% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 68% | 2 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIO’s FA Score shows that 1 FA rating(s) are green while DHR’s FA Score has 1 green FA rating(s).
- BIO’s FA Score: 1 green, 4 red.
- DHR’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIO’s TA Score shows that 5 TA indicator(s) are bullish while DHR’s TA Score has 4 bullish TA indicator(s).
- BIO’s TA Score: 5 bullish, 4 bearish.
- DHR’s TA Score: 4 bullish, 6 bearish.
Price Growth
BIO (@Medical/Nursing Services) experienced а -8.25% price change this week, while DHR (@Medical Specialties) price change was -5.20% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.19%. For the same industry, the average monthly price growth was -6.00%, and the average quarterly price growth was -2.76%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.42%. For the same industry, the average monthly price growth was +3.09%, and the average quarterly price growth was +45.49%.
Reported Earning Dates
BIO is expected to report earnings on Oct 22, 2026.
DHR is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Medical/Nursing Services (-2.19% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (-3.42% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
BIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -4.42% | ||
| TMO - DHR | 73% Closely correlated | -3.34% | ||
| RGEN - DHR | 68% Closely correlated | -7.80% | ||
| BIO - DHR | 64% Loosely correlated | -5.86% | ||
| A - DHR | 60% Loosely correlated | -3.27% | ||
| BRKR - DHR | 58% Loosely correlated | -4.34% | ||
More | ||||